Inter Pharma Public Company (IP) Fair Value & Analysis
Healthcare · TH · Market cap 2.7B THB
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 7.02 THB to 4.45 THB (−36.6%) since Jun 23, 2026. Share price +4.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 2.87 THB – 4.43 THB · fair‑value band 3.34 THB – 5.56 THB · the 4.34 THB price screens below the 4.45 THB fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Inter Pharma Public Company (IP) currently trades at 4.34 THB, while our model-based Fair Value estimate is 4.45 THB — implying the stock looks roughly 2.5% undervalued today. We read business quality at 84/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Inter Pharma Public Company generated revenue of 2.2B THB at a net margin of 5.9%. Revenue grew 5.3% year over year. It earns a return on equity of 6.5%. Net debt stands at 120M THB. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Inter Pharma Public Company Limited manufactures, imports, and distributes drug and dietary supplement products for humans and animals in Thailand. It operates through three segments: Human healthcare, Animal healthcare, and Hospital and clinics. The company offers healthcare, anti-aging, and human beauty products, such as medical supplies, nutrition therapy, cosmetics, supplementary food, probiotic and prebiotic products, health and general food products, pharmaceuticals and cosmeceuticals products, functional food and drinks, and medical equipment and medicines, etc. It also provides pet healthcare and livestock products, such as medical supplies, nutrition therapy, vaccine, supplementary food, probiotic and prebiotic products, animal health food products, animal food, general formula animal food, nutraceuticals and medicine companion products, ear and teeth cleaners, pee pads, shampoos, and medical equipment related to pet and livestock care product, etc. In addition, the company…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Inter Pharma Public Company reported revenue of 2.2B THB in FY2025 versus 909M THB in FY2021, a compound +24.6%/yr. Reported net income was 122M THB in FY2025, compounding +3.9%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Inter Pharma Public Company (IP) undervalued?
What is the fair value of IP?
What is the quality score of IP?
What is the revenue of Inter Pharma Public Company (IP)?
What is the net profit margin of IP?
Does Inter Pharma Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.